Pancreatic Cancer Research

ResearcherMemorial Sloan Kettering Cancer CenterActive in the last 2 years

F. Huguet

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5302-5784; OpenAlex author ID A5022701871. Sources: OpenAlex.

Their work

Papers
25 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
90
Papers, trials and grants by year

2012: 2 papers · 2013: 2 papers · 2014: 1 paper · 2015: none · 2016: 6 papers · 2017: 3 papers · 2018: 2 papers · 2019: 1 paper · 2020: none · 2021: 2 papers · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: 1 paper · 2026: 3 papers

Papers 25

  1. The European Multidisciplinary Evidence-Based Guideline on Pancreatic Cancer: Methodological Protocol. Co-author DOI 10.1002/gin2.70074↗
  2. Current practices and challenges in the management of nonmetastatic pancreatic adenocarcinoma: results of an EORTC survey. Co-author DOI 10.1016/j.esmogo.2026.100372↗
  3. The OligoPanc project: an interdisciplinary expert consensus statement on oligometastatic pancreatic cancer. Co-author DOI 10.1016/s1470-2045(25)00714-4↗
  4. Hypofractionated radiotherapy for pancreatic cancer: What role in 2025? First author DOI 10.1016/j.canrad.2025.104676↗
  5. Radiation therapy for locally advanced pancreatic adenocarcinoma: a therapeutic option which should not be forgotten. Letter to the Editor regarding: "Pancreat… Co-author DOI 10.1016/j.annonc.2024.05.003↗
  6. Neoadjuvant treatment of pancreatic adenocarcinoma: Chemoradiation or stereotactic body radiation therapy? Co-author DOI 10.1016/j.canrad.2022.06.020↗
  7. ESTRO ACROP guidelines for target volume definition in pancreatic cancer. Co-author DOI 10.1016/j.radonc.2020.07.052↗
  8. The role of radiotherapy in locally advanced pancreatic cancer. Co-author DOI 10.1259/bjr.20210044↗
  9. How Does Chemoradiotherapy Following Induction FOLFIRINOX Improve the Results in Resected Borderline or Locally Advanced Pancreatic Adenocarcinoma? An AGEO-FRE… Co-author DOI 10.1245/s10434-018-6931-6↗
  10. [Role of radiation therapy in the management of pancreatic cancer]. Co-author DOI 10.1016/j.canrad.2018.06.005↗
  11. Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC). Co-author DOI 10.1016/j.dld.2018.08.008↗
  12. 3rd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of pancreatic cancer. Co-author DOI 10.1016/j.ejca.2017.03.022↗
  13. Chemoradiation for Unresectable Pancreatic Cancer Can Improve Quality of Life and Does Not Exclude Potential Resection. Co-author DOI 10.1016/j.ijrobp.2017.05.032↗
  14. Chemotherapy and intensity-modulated radiation therapy for locally advanced pancreatic cancer achieves a high rate of R0 resection. Co-author DOI 10.1080/0284186x.2016.1245862↗
  15. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Wi… First author DOI 10.1001/jama.2016.4324↗
  16. Afatinib, an Irreversible EGFR Family Inhibitor, Shows Activity Toward Pancreatic Cancer Cells, Alone and in Combination with Radiotherapy, Independent of KRAS… Co-author DOI 10.1007/s11523-015-0403-8↗
  17. [Radiation therapy of pancreatic cancer]. Co-author DOI 10.1016/j.canrad.2016.07.036↗
  18. Current standards and new innovative approaches for treatment of pancreatic cancer. Co-author DOI 10.1016/j.ejca.2015.12.026↗
  19. Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer. Co-author DOI 10.1016/j.molonc.2016.01.006↗
  20. Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP). First author DOI 10.1038/bjc.2016.212↗
  21. Locally advanced pancreatic cancer: the role of definitive chemoradiotherapy. Co-author DOI 10.1016/j.clon.2014.06.002↗
  22. Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial. First author DOI 10.1093/annonc/mdt176↗
  23. Does pre-operative chemoradiation for initially unresectable or borderline resectable pancreatic adenocarcinoma increase post-operative morbidity? A case-match… Co-author DOI 10.1111/hpb.12033↗
  24. Radiotherapy technical considerations in the management of locally advanced pancreatic cancer: American-French consensus recommendations. Co-author DOI 10.1016/j.ijrobp.2011.11.050↗
  25. FOLFIRINOX in locally advanced pancreatic cancer: the starting point for questioning. Co-author DOI 10.1097/mpa.0b013e3182496e90↗

Closest collaborators

The 25 strongest of 90 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Christelle Bouchart · 2 shared papers, 2024–2026 · strength 0.56
  2. Pauline Kordalski · 1 shared paper, 2025 · strength 0.54
  3. V. Vendrely · 4 shared papers, 2017–2024 · strength 0.53
  4. António Sá Cunha · 3 shared papers, 2018–2026 · strength 0.49
  5. Cindy Neuzillet · 2 shared papers, 2018–2026 · strength 0.42
  6. Jean‐Baptiste Bachet · 5 shared papers, 2013–2021 · strength 0.40
  7. Mauro Loi · 2 shared papers, 2022–2024 · strength 0.36
  8. Matthieu Delaye · 1 shared paper, 2026 · strength 0.36
  9. Ingrid Garajová · 1 shared paper, 2026 · strength 0.36
  10. M. Hawkins · 2 shared papers, 2021–2024 · strength 0.33
  11. Pascal R. Hammel · 5 shared papers, 2013–2018 · strength 0.30
  12. Sébastien Gaujoux · 3 shared papers, 2013–2021 · strength 0.27
  13. Jean‐Luc Van Laethem · 4 shared papers, 2016–2017 · strength 0.21
  14. Anna M E Bruynzeel · 1 shared paper, 2024 · strength 0.20
  15. Marta Scorsetti · 1 shared paper, 2024 · strength 0.20
  16. Eva Versteijne · 1 shared paper, 2024 · strength 0.20
  17. Joost J.M.E. Nuyttens · 1 shared paper, 2024 · strength 0.20
  18. Somnath Mukherjee · 2 shared papers, 2014–2021 · strength 0.20
  19. Christophe Louvet · 4 shared papers, 2013–2016 · strength 0.19
  20. Olivier Bouché · 3 shared papers, 2013–2018 · strength 0.14
  21. Karyn A. Goodman · 3 shared papers, 2012–2017 · strength 0.14
  22. Fabienne Portales · 2 shared papers, 2018–2019 · strength 0.14
  23. Julien Taı̈eb · 2 shared papers, 2018–2019 · strength 0.14
  24. Robert C Krempien · 1 shared paper, 2021 · strength 0.13
  25. Alessio Giuseppe Morganti · 1 shared paper, 2021 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.